BG8 LewisY – MMab

For In Vitro Diagnostic Use

Blood group antigens have been examined as potential discriminators between Pulmonary Adenocarcinoma (PACA) and Epithelioid Mesothelioma (EM). LewisY is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and is able to distinguish between PACA and EM. Studies of 231 cases of PACA and 197 cases of EM have shown that sensitivity and specificity for PACA were both 93%. It has been reported that sensitivity of nonmesothelial antigens for Adenocarcinoma is organ dependent, with BG8 Lewis performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8.
It has been concluded using logical regression analysis that a three-antibody immunohistochemical panel including Calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from Adenocarcinoma in a variety of sources (lung, ovary, breast, stomach).

Antibody Type: Mouse Monoclonal
Isotype: IgM
Localization: Cytoplasmic, Membranous
Clone: F3
Reactivity: Paraffin, Frozen
Control: Placenta, Tonsil, Pancreas, Cervix, Bladder TCC, Lung Adenocarcinoma

BG8 LewisY is an antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.